Program
lotilaner
Also written as “TP-03”, “Low Dose TP-05” and “High Dose TP-05”.
Its studies are mostly in Blepharitis · Rosacea · Meibomian Gland Dysfunction · Lyme Disease · Colitis, Ulcerative, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tarsus Pharmaceuticals | 81 open or running | phase 3since Jul 14, 2020 | Jul 14, 2020 | Dec 31, 2026phase 2 · NCT07443202 |
| LianBio | 10 open or running | phase 3since Nov 17, 2022 | Nov 17, 2022 | none ahead |
| Zeria Pharmaceutical | 10 open or running | phase 3since Jul 9, 2013 | Jul 9, 2013 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 9, 2013First study: phase 3 study in Acute Ulcerative ColitisNew to Zeria PharmaceuticalZeria Pharmaceutical · NCT01903252 · 817 enrolled · Switzerland
- Jul 14, 2020Tarsus Pharmaceuticals's first study: phase 3 study in BlepharitisNew to Tarsus PharmaceuticalsTarsus Pharmaceuticals · NCT04475432 · 421 enrolled · United States
- Mar 2, 2021Phase 3 study in BlepharitisTarsus Pharmaceuticals · NCT04784091 · 412 enrolled · United States
- Jul 22, 20212 phase 1 studies in HealthyTarsus Pharmaceuticals · NCT05138861, NCT05138796
- May 3, 2022Phase 2 study in Lyme DiseaseTarsus Pharmaceuticals · NCT05387083 · 30 enrolled · United States
- Jun 27, 2022Phase 2 study in Meibomian Gland DysfunctionTarsus Pharmaceuticals · NCT05454956 · 39 enrolled · United States
- Nov 17, 2022LianBio's first study: phase 3 study in BlepharitisNew to LianBioLianBio · NCT05629390 · 163 enrolled · China
- Jan 31, 2023Phase 1 study in HealthyTarsus Pharmaceuticals · NCT05720364 · 42 enrolled · United States
- Feb 24, 2026Phase 2 study in RosaceaTarsus Pharmaceuticals · NCT07443202 · 155 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 2 study in RosaceaTarsus Pharmaceuticals · NCT07443202
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07443202Rosacea · United States | 2 | By invitation | Tarsus Pharmaceuticals | Dec 31, 2026 | 155 |
| NCT05720364Healthy · United States | 1 | Completed | Tarsus Pharmaceuticals | May 30, 2023 | 42 |
| NCT05629390Blepharitis · China | 3 | Completed | LianBio | Sep 15, 2023 | 163 |
| NCT05454956Meibomian Gland Dysfunction · United States | 2 | Completed | Tarsus Pharmaceuticals | May 18, 2023 | 39 |
| NCT05387083Lyme Disease · United States | 2 | Completed | Tarsus Pharmaceuticals | Jun 26, 2024 | 30 |
| NCT05138861Healthy · Canada | 1 | Completed | Tarsus Pharmaceuticals | Sep 3, 2021 | 24 |
| NCT05138796Healthy · United States | 1 | Completed | Tarsus Pharmaceuticals | Mar 25, 2022 | 67 |
| NCT04784091Blepharitis · United States | 3 | Completed | Tarsus Pharmaceuticals | May 9, 2022 | 412 |
| NCT04475432Blepharitis · United States | 3 | Completed | Tarsus Pharmaceuticals | May 4, 2021 | 421 |
| NCT01903252Acute Ulcerative Colitis · Switzerland | 3 | Completed | Zeria Pharmaceutical | May 2016 | 817 |
How it is read
Names in the registry
- “TP-03”, 2 entries
- “lotilaner”, 1 entry
- “Low Dose TP-05”, 1 entry
- “High Dose TP-05”, 1 entry
- “Lotilaner”, 1 entry
Codes read as this program: TP03, TP05.
Conditions, from the studies’ own filings
- Blepharitis, 3 studies
- Rosacea, 1 study
- Meibomian Gland Dysfunction, 1 study
- Lyme Disease, 1 study
- Colitis, Ulcerative, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.